Evidence map›Paper›PMID 40531296›Full record

ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2025

Perioperative versus adjuvant chemotherapy in carcinoma stomach-A retrospective propensity-matched analysis.

Archana Elangovan, Prasanth Penumadu, Biswajit Dubashi, N Sreekumaran Nair, Balasubramanian A

Abstract read
PubMed Publisher
In one paragraph

Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Archana ElangovanDepartment of Surgical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605 006, India.
Prasanth PenumaduDepartment of Surgical Oncology, Sri Venkateswara Institute of Cancer Care and Advanced Research, Tirupati, 517 501, India. drpenumadu@gmail.com.ORCID http://orcid.org/0000-0002-2189-5056
Biswajit DubashiDepartment of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605 006, India.
N Sreekumaran NairDepartment of Biostatistics, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605 006, India.
Balasubramanian ADepartment of Surgical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605 006, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA uniform consensus on the optimal sequencing of treatment modalities in locally advanced gastric cancer is not reached due to conflicting results worldwide. We conducted a retrospective propensity-matched analysis to compare survival of locally advanced gastric cancer patients who were treated with peri-operative chemotherapy followed by surgery or upfront surgery followed by adjuvant chemotherapy.

methodsDeidentified records of prospectively maintained data of locally advanced gastric cancer patients treated from 2015 to 2020 were collected. A 1:1 propensity matching with a tolerance limit of 0.2 was performed. The outcome variables including recurrence-free and overall survival were compared among the matched groups using log-rank tests and Cox proportional hazards analysis was performed.

resultsTwo hundred patients (64 in peri-operative chemotherapy and 136 in the upfront surgery group) were included in the study. Variables including age group, sex, gastric outlet obstruction, tumor site, clinical T stage and node positivity were used for matching. The median overall survival and recurrence-free survival were found to be 21.90 months (95% CI = 13.30-30.49) and 15.08 months (95% CI = 8.17-21.98), respectively, in the peri-operative chemotherapy arm and 18.70 months (95% CI = 11.88-25.51) and 13.49 months (95% CI = 6.76-20.21), respectively, in upfront surgery arm with no significant difference (median follow-up 42 months). Patients who presented with pallor had Borrmann type 4 on endoscopy, received lesser number of chemotherapy cycles, lymph node ratio was > 0.13 and perineural invasion were associated with worse overall survival and recurrence-free survival.

conclusionIn this real-world scenario, retrospective propensity-matched study, no difference was noted in overall survival and recurrence-free survival between patients who received peri-operative chemotherapy or upfront surgery followed by adjuvant chemotherapy in locally advanced gastric cancer.

Indexed as

AdjuvantCarcinoma stomachChemotherapyGastrectomyPeri-operative

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.